Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies.


Journal

Patient education and counseling
ISSN: 1873-5134
Titre abrégé: Patient Educ Couns
Pays: Ireland
ID NLM: 8406280

Informations de publication

Date de publication:
09 2019
Historique:
received: 21 12 2018
revised: 25 03 2019
accepted: 25 04 2019
pubmed: 12 5 2019
medline: 14 4 2020
entrez: 12 5 2019
Statut: ppublish

Résumé

To identify factors limiting and facilitating patient-centered communication (PCC) in the United States hematology-oncology setting, with a focus on multiple myeloma (MM), given the limited attention to PCC and rapid pace of change that has taken place in this setting. A literature search was performed from 2007 to 2017 to identify published articles and congress abstracts related to clinician-patient communication and treatment decision-making in oncology. Search results were evaluated by year of publication and disease area. A thematic assessment was performed to identify factors limiting and promoting PCC for patients with MM and other hematologic malignancies. Of the 6673 publications initially retrieved, 18 exclusively reported findings in patients with hematologic malignancies and were included in this review. We identified three critical, but modifiable, barriers to PCC in the hematologic malignancy setting, including insufficient information exchange, treatment goal misalignment, and discordant role preferences in treatment decision-making. Factors that enhanced interaction quality included educational programs for clinicians and patients. Patients with MM and other hematologic malignancies experience a distinct set of challenges that may affect PCC. Clinicians have the opportunity to improve patient care by proactively addressing the identified barriers and implementing strategies demonstrated to improve PCC.

Identifiants

pubmed: 31076236
pii: S0738-3991(19)30167-3
doi: 10.1016/j.pec.2019.04.028
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

1602-1612

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Thomas W LeBlanc (TW)

Duke Cancer Institute, Durham, NC, USA; Division of Hematological Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: thomas.leblanc@duke.edu.

Walter F Baile (WF)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Susan Eggly (S)

Wayne State University Department of Oncology/Karmanos Cancer Institute, Detroit, MI, USA.

Carma L Bylund (CL)

College of Journalism and Communications, University of Florida, Gainesville, FL, USA; College of Medicine, University of Florida, Gainesville, FL, USA.

Sandra Kurtin (S)

University of Arizona and Arizona Cancer Center, Tucson, AZ, USA.

Monica Khurana (M)

Amgen Inc., Thousand Oaks, CA, USA.

Rani Najdi (R)

Amgen Inc., Thousand Oaks, CA, USA.

Julie Blaedel (J)

Amgen Inc., Thousand Oaks, CA, USA.

Jeffrey L Wolf (JL)

Department of Medicine, Division of Hematology & Oncology, University of California San Francisco, San Francisco, CA, USA.

Rafael Fonseca (R)

Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH